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Abstract
Established treatment regimens for the autosomal dominant hyperimmunoglobulin E syndrome, denominated Job syndrome, 
are lacking. Thus, Job syndrome still exerts a dramatic impact on patients’ quality of life. Our aim was to present safety and 
effectiveness of a regimen including co-trimoxazole, omalizumab and inhaled tobramycin in Job syndrome. A 26-year-old woman 
diagnosed with Job syndrome since infancy through sequencing revealing G342D mutation in STAT3 gene was initiated in the 
above mentioned treatment regimen; she was followed for 6 months, and to date, none recurrent pulmonary or skin infection was 
noticed. Furthermore, a considerable improvement in skin lesions was observed. A combination of anti-IgE and longitudinal use 
of inhaled antibiotics seems well-founded in Job syndrome.
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Introduction
A 26-year-old woman, never smoker, present-
ed to our department with cough, yellow sputum 
and localized left chest pain. Chest radiograph 
revealed consolidation in the left lower lobe and 
a fluid-filled cavity in the middle lobe. She de-
nied the presence of fever, night sweats or weight 
loss. She had a medical history of Job syndrome 
diagnosed during infancy based on compatible 
genetic (G342D mutation in STAT3 gene) and 
clinical (recurrent lower respiratory and skin 
infections in need of repeated hospitalizations 




Physical examination revealed the following 
vital signs: blood pressure of 110/70 mm Hg; 
heart rate, 85 beats/min; temperature, 36,8˚C 
and oxygen saturation, 97% on room air. Lung 
auscultation revealed crackles mainly on left side 
while heart and abdomen examination results 
were unremarkable. There were no palpable 
lymph nodes. Clubbing was present, as well as 
extensive skin lesions on the upper limbs and 
hyperextensibility of finger joints.
Diagnostic studies
The complete blood and metabolic pan-
el revealed elevated white blood cells (WBC) 
(16,1 K/μL) with neutrophilic predominance on 
admission (62%) and eosinophilic predominance 
on discharge (40%) and elevated c-reactive pro-
tein (22,33 mg/dL). Urinalysis and electrocardio-
gram were normal. Chest computed tomography 
(CT) showed cystic bronchiectatic lesions in the 
right upper lobe combined with a fluid-filled 
cavity within the middle lobe and consolidation 
in the left lower lobe (Figure 1). The patient 
underwent conventional bronchoscopy with the 
presence of purulent bronchial secretions bilater-
ally and hemorrhagic mucosa in the middle lobe. 
Culture of washing for common pathogens was 
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positive for Methicillin-resistant Staphylococcus 
aureus (MRSA) infection and negative for myco-
bacterium infection. Cytological examination of 
washing was negative for malignancy. Pulmonary 
function tests showed bronchodilator reversibil-
ity (PRE: forced expiratory volume in 1 second 
[FEV1] / forced vital capacity [FVC]: 83%, FEV1 of 
1.65 L [59% of predicted] and FVC of 2 L [63% 
of predicted] — POST: FEV1/FVC: 87%, FEV1 of 
1.8 L [68% of predicted] and FVC of 2.06 L [66% 
of predicted]). Skin prick test was positive for 
mixed fungus, Tilia tomentosa and Candida. 
Moxifloxacin and linezolid were administered for 
ten days based on antibiogram. An improvement 
on chest radiogram performed four weeks later 
was obvious. This was the sixth hospitalization 
for our patient within the previous year attributed 
to pneumonia following multiple hospitalizations 
since infancy due to recurrent lower respiratory 
or skin infections.
Clinical course
The patient was admitted with recurrent 
pneumonia in setting of diagnosed Job syndrome 
since infancy. Genetic confirmation of the dis-
ease had been conducted through sequencing 
revealing G342D mutation in STAT3 gene. Recent 
laboratory examination had revealed remarkably 
elevated serum IgE levels >30 000 IU/mL and 
eosinophilia (31% WBC count: 9.27 K/μL). During 
her last hospitalization, the patient was treated 
with antimicrobial therapy based on antibiogram, 
as part of symptomatic management of recurrent 
respiratory infections observed throughout the 
clinical course of syndrome. Considering multiple 
hospitalizations and extensive post-infectious 
structural abnormalities of lung parenchyma, 
multidisciplinary approach yielded a therapeutic 
regimen including biological anti-IgE agent and 
longitudinal antibiotics on a chemoprophylac-
tic basis as the optimal strategy. In particular, 
the patient was commenced on co-trimoxazole, 
omalizumab and inhaled tobramycin. Established 
evidence has shown that co-trimoxazole is a safe 
and effective substitution to penicillins and has 
anti-MRSA coverage [1]. Furthermore, omali-
zumab, a monoclonal anti-IgE, has been shown 
closely related to a decline in serum IgE with 
symptomatic improvement especially in atopic 
conditions [2–4]. Eventually, inhaled antibiotics 
have emerged as a new option for specific groups 
of patients, including patients with bronchiecta-
sis, combining high drug concentrations directly 
to the site of infection and concomitantly min-
imizing systemic absorption and potential side 
effects. Co-trimoxazole was administered orally 
in prophylactic dosage three times a week, omali-
zumab in dosage adjusted by the patient’s weight 
and baseline IgE once a month subcutaneously 
and inhaled tobramycin 300 mg twice a day. The 
woman was followed for 6 months, with no recur-
rent respiratory or skin infections. Furthermore, 
a considerable improvement of skin lesions was 
observed (Figure 2). To the extent of our knowl-
edge, this is the first time that combination of an-
ti-IgE and longitudinal use of inhaled antibiotics 
is proposed in Job syndrome. 
Discussion
Hyperimmunoglobulin E syndrome is a rare 
primary immunodeficiency disorder charac-
terized by eczema, skin abscesses, recurrent 
staphylococcal infections of the skin and lungs, 
pneumatocele formation, candidiasis, eosinophil-
ia, and elevated serum levels of IgE [5]. It was 
Figure 1. Chest computed tomography showed cystic bronchiectasis in the right upper lobe (A), a fluid-filled cavity in the middle lobe (B) and 
consolidation in the left lower lobe (C)
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first described as “Job syndrome” by David et al. 
in 1966 in two patients with eczema, recurrent 
pulmonary infections and cold lung abscesses 
and was later associated by Buckley et al. in 
1972 with increased serum immunoglobulin E 
levels [6]. Job syndrome is classified as the auto-
somal dominant hyper-IgE syndrome, in which 
patients have abnormalities in different systems, 
including the immune system, connective tissue, 
skeletal and vascular structures [7]. It is attributed 
to a mutation in the STAT3 gene in more than 
two-thirds of cases (70%) with the etiology of the 
rest cases remaining unclear [8]. Clinical signs of 
immunological features include recurrent skin 
and pulmonary bacterial or candidiasis infec-
tions. Staphylococcus aureus is the predominant 
pathogen resulting in follicular skin lesions or 
recurrent lung abscesses, bronchiectasis and 
pneumatoceles. Streptococcus pneumoniae and 
Haemophilus are observable less frequently, while 
Aspergillus and Pseudomonas are usual cause of 
chronic colonization of bronchiectasis. The main 
laboratory diagnostic feature is an increase in 
Figure 2. Improvement of skin lesions following administration of omalizumab for 6 months
A B
serum IgE levels of more than 2000 IU/mL. Eosin-
ophilia is observed in more than 90% of the pa-
tients while WBC count can be normal, elevated 
or reduced in number [9]. The established treat-
ment is the long-term, sometimes consecutive, 
use of antibiotics by adapting the administration 
of antimicrobial agents to opportunistic infections 
occurring in affected patients, and in selected 
cases, applying surgical procedures during ab-
scess development. In order to overcome purely 
symptomatic treatment applied for the moment, 
biological treatment with monoclonal antibodies 
or combination of biologics and antibiotics could 
be an optimal strategy. Further studies towards 
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